BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics announced a share consolidation plan, converting every fifteen pre-consolidation shares into one post-consolidation share to meet Nasdaq listing requirements. The consolidation, effective January 24, 2025, will see the new shares trading from January 29, 2025, ensuring continued compliance and adjusted securities pricing.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.